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ABSTRACT
In a meta-analysis published in June 2003, we reported that new and old classes
of antihypertensive drugs had similar long-term efficacy and safety. To test
whether our previous conclusions would hold, we updated our quantitative
overview with new information from clinical trials published before 2005. To
compare new and old antihypertensive drugs, we computed pooled odds ratios
from stratified 2 × 2 contingency tables. Compared with old drugs (diuretics
and β-blockers), calcium-channel blockers, angiotensin converting-enzyme
inhibitors and AR1 blockers provided similar overall cardiovascular protection.
However, the published results suggested that dihydropyridine calcium-
channel blockers might offer a selective benefit in the prevention of stroke and
inhibitors of the renin–angiotensin system in the prevention of heart failure. For
prevention of myocardial infarction, the published results were more equivocal
because of the benefit of amlodipine over placebo or valsartan in two trials,
whereas other placebo-controlled trials of calcium-channel blockers or ACE
inhibitors did not substantiate the expected benefit with regard to cardiac out-
comes. In conclusion, the present results suggested that all antihypertensive
drugs provide similar overall cardiovascular protection. To what extent within
trial differences in blood pressure, rather than specific ancillary properties,
might account for the observed outcome results in individual trials will be
discussed in Chapter 30.
INTRODUCTION
Hypertension affects from 20% to 30% of the world’s population and is a major
cardiovascular risk factor [1,2]. The relation between cardiovascular risk and
blood pressure is continuous, consistent across the age range, present in all
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ethnic groups and independent of other risk factors [1,2]. The ultimate goal of
any blood pressure lowering therapy is to reverse the risk associated with an ele-
vated blood pressure and to prevent the cardiovascular complications associated
with hypertension [3,4].
Placebo-controlled clinical trials proved that blood pressure lowering with
various drug classes including diuretics, β–blockers, calcium-channel blockers,
angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type-1
receptor (AR1) blockers reduces the incidence of cardiovascular complications.
Over the past decade, clinical trials of blood pressure lowering drugs shifted
focus from placebo-controlled to actively controlled designs in hypertensive
patients and from primary to secondary prevention in high-risk patients with or
without hypertension. The research goal underlying many of the more recent tri-
als was to prove that the new classes of antihypertensive drugs provide superior
protection against cardiovascular complications, especially in patients with a
previous history of cardiovascular disease such as coronary heart disease or
stroke. The aim of the present review was to summarize the main results of these
studies in the light of the overall evidence from clinical trials in hypertension.
NEW VS. OLD ANTIHYPERTENSIVE DRUGS
In consecutive quantitative overviews of the actively controlled outcome trials
[5–7], we computed pooled estimates for the comparison of new antihypertensive
drugs, such as calcium-channel blockers, ACE inhibitors, AR1 blockers and
α–blockers, with conventional therapy consisting of diuretics and/or β–blockers.
In 2003 [7], we reviewed 18 reports on 15 trials [8–25], in which 1 20 574 patients
had been randomized. Table 29.1 summarizes the characteristics of the trials
comparing new antihypertensive drugs with conventional therapy, which were
published in 2002 or later.
To compare new and old antihypertensive drugs, we computed pooled odds
ratios from stratified 2 × 2 contingency tables. If Zelen’s test of heterogeneity was
significant, we used a random effects model.
Calcium-channel blockers vs. conventional therapy
For the comparison of calcium-channel blockers with conventional therapy, our
last review [7] considered nine trials [8,10–13,19–21,26] with 67 435 randomized
patients. These trials were ALLHAT/Aml [21], CONVINCE [19], ELSA [20,22],
INSIGHT [12], MIDAS [8], NICS [10], NORDIL [13], STOP2/CCBs [11] and
VHAS [26]. For none of the outcomes considered in these analyses, including
total and cardiovascular mortality, all cardiovascular events (Fig.29.1), stroke
(Fig. 29.2), myocardial infarction (Fig. 29.3) or heart failure, heterogeneity among
the trials reached statistical significance [7].
The pooled odds ratios expressing possible benefit of calcium-channel block-
ers over old drugs were close to unity and nonsignificant for total mortality (0.98;
95% confidence interval (CI), 0.92–1.03; P = 0.42), cardiovascular mortality (1.03;
CI, 0.95–1.11; P = 0.51), all cardiovascular events (1.03; CI, 0.99–1.08; P= 0.15)
and myocardial infarction (1.02; CI, 0.95–1.10; P = 0.61). Calcium-channel block-
ers provided slightly better protection against fatal and nonfatal stroke than
old drugs (Fig.29.2). For the nine trials combined [8,10–12,20,21,26–28], the
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pooled odds ratio for stroke was 0.92 (CI, 0.84–1.01; P = 0.07). After exclusion of
CONVINCE [28], a large trial based on verapamil, the odds ratio for stroke was
0.90 and reached significance (CI, 0.82–0.98; P = 0.02). For heart failure, calcium-
channel blockers provided less protection than conventional therapy, regardless
of whether (1.33; CI, 1.22–1.44; P < 0.0001) or not (1.33; CI, 1.22–1.46; P < 0.0001),
we incorporated the CONVINCE trial [28] in the pooled estimates.
A rerun of the analysis in December 2004 with coronary heart disease and
stroke as the outcomes of interest confirmed the above results [7]. In addition to
the nine trials [8,10–12,20,21,26–28] previously reviewed, we also included
INVEST [29] and SHELL [30], but not AASK because published information on
cause-specific cardiovascular complications was not enough detailed [31]. The
P-values for heterogeneity remained nonsignificant. Pooled estimates were 1.02
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All cardiovascular events
Trials Number of
events/patients
Odds ratios
(95% Cls)
Difference
(SD)
MIDAS/NICS/VHAS
STOP2/CCBs
NORDIL
INSIGHT
ALLHAT/Aml
ELSA
CCBs without CONVINCE
Hetergeneity P = 0.78
CONVINCE
All CCBs
Heterogeneity P = 0.86
UKPDS
STOP2/ACEIs
CAPPP
ALLHAT/Lis
ANBP2
All ACEIs
Heterogeneity P = 0.006
LIFE
SCOPE
All ARBs
Heterogeneity P = 0.69
ALLHAT/Dox
All trials *
Heterogeneity P < 0.0001
Old
37 /1358
637 /2213
453 /5471
397 /3164
3941 /15255
33 /1157
5498 /28618
365 /8297
5863 /36915
78 /358
637/2213
401/5493
3941/15255
429 /3039
5486 /26358
588 /4588
268 /2460
856 /7048
2245 /15268
7627/52853
New
39 /1353
636 /2196
466 /5410
383 /3157
2432 /9048
27/1177
3983 /22341
364 /8179
4347/30520
107/400
586 /2205
438 /5492
2514 /9054
394 /3044
4039 /20195
508 /4605
242 /2477
750 /7082
1592 /9067
10728 /66864
3.6% (2.4) 2P = 0.14
3.4% (2.3) 2P = 0.15
2.6% (3.6) 2P = 0.59
−14.3% (5.5) 2P = 0.004
1.4% (4.8) 2P = 0.69
0 1 2 3
New drugs
better
Old drugs
better
Fig. 29.1 Effects of antihypertensive treatment on all cardiovascular events in trials comparing
new with old antihypertensive drugs. Asterisks indicate significant heterogeneity and pooled esti-
mates calculated from a random effects model. Solid squares represent the odds ratios in trials and
have a size proportional to the number of events. The 95% confidence intervals for individual trials
are denoted by lines and those for pooled odds ratios by diamonds. Acronyms of trials are
explained in a separate section of this article. Reproduced with permission from Ref. [7]. For
update, including SHELL [30] and INVEST [29], see section new vs. old antihypertensive drugs.
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Fatal and non − fatal stroke
Trials Number of 
events/patients
Odds ratios
(95% Cls)
Difference
(SD)
Old New
MIDAS/NICS/VHAS
STOP2/CCBs
NORDIL
INSIGHT
ALLHAT/Aml
ELSA
CCBs without CONVINCE
Heterogeneity P = 0.68
CONVINCE
All CCBs
Heterogeneity P = 0.39
      
UKPDS
STOP2/ACEIs
CAPPP
ALLHAT/Lis
ANBP2
All ACEIs
Heterogeneity P = 0.16
    
LIFE
SCOPE
ALL ARBs
Heterogeneity P = 0.99
ALLHAT/Dox
All trials *
Heterogeneity P = 0.001
15 /1358
237 /2213
196 /5471
74 /3164
675 /15255
14 /1157
1211 /28618
118 /8297
1329 /36915
17/358
237/2213
148 /5493
675 /15255
107/3039
1184 /26358
309 /4588
115 /2460
424 /7048
351 /15268
2025 /52853
19 /1353
207/2196
159 /5410
67/3157
377/9048
9 /1177
838 /22341
133 /8179
971 /30520
21 /400
215 /2205
189 /5492
457 /9054
112 /3044
994 /20195
232 /4605
89 /2477
321 /7082
244 /9067
2530 /66864
−10.2% (4.8) 2P = 0.02
−7.6% (4.4) 2P = 0.07     
10.2% (4.6) 2P = 0.03
−24.4% (8.0) 2P = 0.0002
−2.5% (5.4) 2P = 0.64
0 1 2 3
New drugs
better
Old drugs
better
Fig. 29.2 Effects of antihypertensive treatment on fatal and nonfatal stroke in trials comparing
new with old antihypertensive drugs. The asterisk indicates significant heterogeneity and pooled
estimates calculated from a random effects model.
For further explanation see Fig. 29.1. Reproduced with permission from Ref. [7]. For update, includ-
ing SHELL [30] and INVEST [29], see section new vs. old antihypertensive drugs.
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(CI, 0.96–1.09; P = 0.55) and 0.92 (CI, 0.85–0.99; P = 0.03) for coronary heart dis-
ease and stroke, respectively. After exclusion of the two verapamil-based trials
[28,29], the common odds ratio for stroke was 0.90 (CI, 0.82–0.98; P = 0.02).
ACE inhibitors vs. conventional therapy
Our 2003 review [7] considered six trials [9,11,16,21,23,25] with 47 519 random-
ized patients, which compared ACE inhibitors with old drugs. These trials
24
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Fatal and non−fatal myocardial infarction
Trials Number of
events/patients
Odds ratios
(95% Cls)
Difference
(SD)
Old New
MIDAS/NICS/VHAS
STOP2/CCBs
NORDIL
INSIGHT
ALLHAT/Aml
ELSA
CCBs without CONVINCE
Heterogeneity P = 0.38
UKPDS
STOP2/ACEIs
CAPPP
ALLHAT/Lis
ANBP2
All ACEIs 
Heterogeneity P = 0.26
CONVINCE
All CCBs
Heterogeneity P = 0.14  
All trials
Heterogeneity P = 0.32
LIFE
SCOPE
All ARBs
Heterogeneity P = 0.92
16 /1358
154 /2213
157/5471
61 /3164
1362 /15255
17/1157
1767/28618
16 /1358
179 /2196
183 /5410
77/3157
798 /9048
18 /1177
1271/22341
46 /358
154 /2213
161/5493
1362 /15255
82 /3039
1805 /26358
61/400
139 /2205
162 /5492
796 /9054
58 /3044
1216 /20195
166 /8297
1933 /36915
133 /8179
1404 /30520
ALLHAT/Dox
188 /4588
63 /2460
251 /7048
198 /4605
70 /2477
268 /7082
608 /15268
2473 /52853
365 /9067
3253 /66864
4.5% (3.9) 2P = 0.26
1.9% (3.7) 2P = 0.61
−3.3% (4.0) 2P = 0.39
7.8% (9.5) 2P = 0.42
0.4% (2.7) 2P = 0.88
0 1 2 3
New drugs
better
Old drugs
better
Fig. 29.3 Effects of antihypertensive treatment on fatal and nonfatal myocardial infarction in trials
comparing new with old antihypertensive drugs. For further explanation see Fig. 29.1. Reproduced
with permission from Ref. [7]. For update, including SHELL [30] and INVEST [29], see section new
vs. old antihypertensive drugs.
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included: ALLHAT/Lis [21], ANBP2 [23], CAPPP [9], HYVET/AD [25],
STOP2/ACEIs [11] and UKPDS/CA [16]. For total and cardiovascular mortality,
stroke (Fig.29.2) and myocardial infarction (Fig.29.3), P-values indicating hetero-
geneity among these trials were nonsignificant. In contrast, for all cardiovascu-
lar events (Fig.29.1) and heart failure heterogeneity was significant due to the
ALLHAT findings [21]. Compared to chlorthalidone [21], the ALLHAT patients
allocated lisinopril had greater risks of stroke (1.15; CI, 1.02–1.30; P = 0.02),
heart failure (1.19; CI, 1.07–1.31; P < 0.001), and hence combined cardiovascular
disease (1.10; CI, 1.05–1.16; P < 0.001).
The pooled odds ratios expressing possible benefit of ACE inhibitors over
conventional therapy were close to unity and nonsignificant for total mortality
(1.00; CI, 0.94–1.06; P = 0.89), cardiovascular mortality (1.02; CI, 0.94–1.11; P =
0.61), all cardiovascular events (1.03; CI, 0.94–1.12; P = 0.59), myocardial infarc-
tion (0.97; CI, 0.90–1.04; P = 0.39) and heart failure (1.04; CI, 0.89–1.22; P = 0.64).
Compared to old drugs, ACE inhibitors gave slightly less protection against
stroke with a pooled odds ratio of 1.10 (CI, 1.01–1.20; P = 0.03). A further review
of the literature in December 2004 did not reveal new trials comparing ACE
inhibitors to diuretics in addition to the six studies already analyzed in 2003 [7].
The AASK trial [31] incorporated a comparison of ramipril with metoprolol, but
only provided aggregate cardiovascular outcomes and could therefore not be
included.
AR1 blockers vs. conventional therapy
The LIFE trial (Table 29.2) tested losartan vs. atenolol as first-line treatment in
hypertensive patients with left ventricular hypertrophy [17,18]. SCOPE [24]
was set up as a double-blind placebo-controlled trial. However, open-label
antihypertensive drugs, which mainly consisted of diuretics, β–blockers or
both classes of old drugs, were added to the double-blind study medication in
a considerably greater proportion of the patients randomized to placebo
than in those allocated candesartan. There was no statistical heterogeneity
between the results of these two trials [7]. Compared to control, treatment ini-
tiated with an AR1 blocker provided similar protection against total mortality,
cardiovascular death and myocardial infarction. The pooled odds ratios
were 0.91 (CI, 1.81–1.02; P = 0.09), 0.89 (CI, 0.77–1.04; P = 0.15) and 1.08
(CI, 0.90–1.29; P = 0.42), respectively. The corresponding estimates for stroke
and all cardiovascular events were 0.77 (CI, 0.65–0.88; P = 0.0002) and 0.86
(CI, 0.77–0.95; P = 0.004), respectively.
New drugs vs. old antihypertensive drugs
Our 2003 review demonstrated that across 15 trials [8–21,23–25] outcomes for
total and cardiovascular mortalityas well as for myocardial infarction (Fig. 29.3)
were consistent. The pooled odds ratios did not deviate from unity, averaging
0.98 (CI, 0.94–1.02; P = 0.38), 1.00 (CI, 0.95–1.07; P = 0.88) and 1.00 (CI, 0.95–1.06;
P = 0.87), respectively. In contrast, for all cardiovascular events (Fig. 29.1), stroke
(Fig. 29.2) and heart failure, there was significant heterogeneity (P < 0.001) across
the 15 trials [8–21,23–25], which was largely due to the ALLHAT results
[14,21,32]. First-line therapy with a diuretic provided less benefit than amlodip-
ine and doxazosin with regard to heart failure than lisinopril and doxazosin in
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the prevention of stroke. For all cardiovascular events and stroke the overall
odds ratios were 1.01 (CI, 0.95–1.09; P = 0.69) and 0.98 (CI, 0.88–1.08; P = 0.64),
respectively. Compared to conventional therapy, new drugs offered less protec-
tion against heart failure with a pooled odds ratio of 1.23 (CI, 1.03–1.47; P = 0.02).
CALCIUM-CHANNEL BLOCKERS VS. AR1 BLOCKERS
Two secondary prevention trials (Table 29.2), IDNT2 [33–35] and VALUE
[36–40], allowed a direct comparison between a dihydropyridine calcium-
channel blocker and an AR1 blocker.
In the IDNT2 trial [33], 1715 hypertensive patients with nephropathy due to
type-2 diabetes were randomized to placebo, irbesartan (300 mg/day) or
amlodipine (10 mg/day). The primary endpoint was a composite of a doubling
of the baseline serum creatinine concentration, the development of end-stage
renal disease or death from any cause. The adjusted relative risk of the primary
endpoint was 0.81 (CI, 0.67–0.99; P = 0.03) for irbesartan vs. placebo and 0.76
(CI, 0.63–0.92; P = 0.005) for irbesartan vs. amlodipine with no difference
between amlodipine and placebo 1.07 (CI, 0.89–1.29; P = 0.47). Doubling of the
serum concentration of creatinine mainly underlay these results because the
between-group differences in the other constituents of the composite endpoint
were not statistically significant [33]. The incidence of cardiovascular events
was similar among the three groups. However, among the components of the
composite cardiovascular outcome, there was a trend toward a decrease in
strokes in patients receiving amlodipine vs. those randomized to placebo (haz-
ard ratio, 0.62; CI, 0.35–1.22; P = 0.18). Likewise, patients receiving amlodipine
had a significantly lower rate of myocardial infarction when compared to
placebo recipients (0.58; CI, 0.37–0.92; P = 0.02). In contrast, patients receiving
irbesartan experienced a lower incidence of heart failure than the placebo group
(0.72; CI, 0.52–1.00; P = 0.048) or the patients randomized to amlodipine (0.65;
CI, 0.48–0.87; P = 0.004).
The VALUE investigators undertook a double-blind clinical trial to test the
hypothesis that, for the same degree of blood pressure lowering, inhibition of the
renin system at the level of the AR1 would be more effective in the prevention of
cardiac morbidity and mortality than calcium-channel blockade [36–40]. Across
943 centers and 31 countries [36,37,39], 15 245 high-risk patients were random-
ized to antihypertensive treatment based on either valsartan (80–160 mg/day) or
amlodipine (5–10 mg/day) and followed-up for a median of 4.2 years. The
VALUE investigators assumed that the primary endpoint, a composite of fatal
and nonfatal cardiac endpoints, would run at a rate of 25 events per 1000 patient-
years [37]. Within less than 5 years, the number of cardiac endpoints exceeded
the projected number of 1450 by 149. Cardiac endpoints occurred at similar rates
in the two treatment groups because the incidence of myocardial infarction was
lower (0.84; CI, 0.72–0.98; P = 0.02) on amlodipine than valsartan, whereas
on amlodipine the risk of heart failure tended to be increased (1.12; CI, 0.97–1.30;
P = 0.12). The incidence of fatal and nonfatal stroke was lower (0.87; CI,
0.74–1.02; P = 0.08) on amlodipine than valsartan. A unique feature of VALUE
was the comprehensive assessment of cardiovascular risk at baseline [37] and
the implementation of a strategy to stabilize risk at a high level across six strata
based on gender and age (50–59, 60–69 and ≥ 70 years).
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PLACEBO-CONTROLLED SECONDARY 
PREVENTION TRIALS
Several secondary prevention trials addressed the question whether new antihy-
pertensive agents given on top of usual therapy, compared to usual antihyperten-
sive therapy, provided superior cardiovascular protection. In five trials with 12
342 randomized patients (Table 29.2) the experimental agent was a dihydropyri-
dine calcium-channel blocker: amlodipine in CAMELOT/Aml [41], PREVENT
[42.43] and IDNT2 [33–35]; nifedipine GITS (gastrointestinal therapeutic system)
in ACTION [44,45]; and nisoldipine in NICOLE [46,47]. In nine trials with 43 227
randomized patients (Table 29.3), the investigational drug was an ACE inhibitor:
enalapril in CAMELOT/En [41] and SCAT [48]; perindopril alone in EUROPA
[49] and PROGRESS/Per [50,51] or in combination with indapamide in
PROGRESS/Com [50,51]; ramipril in DIABHYCAR [52–54], HOPE [55,56] and
PART2 [57]; and trandolapril in PEACE [58]. All patients randomized in these tri-
als were high-risk patients with a history of cardiovascular disease and/or dia-
betes mellitus [54–56], nephropathy [33,35], documented coronary heart disease
[41,43,44,46–49,57,58] or a previous cerebrovascular accident [51,59].
All [33,41,44,49,54,55,58], but five [43,46,48,51,57], placebo-controlled second-
ary prevention trials had a composite primary endpoint (Tables 29.2 and 29.3). In
three trials [41] the composite endpoint included coronary [41,58] or peripheral
[44] revascularization procedures. In four trials the primary endpoint consisted
only of the rate of change of carotid [43,48] or coronary [46,57] atherosclerosis
and hard endpoints, such as stroke or myocardial infarction were only second-
ary outcomes. The use of composite endpoints with varying definitions
(Tables 29.2 and 29.3) and the wide range of secondary endpoints made obtain-
ing pooled estimates for overall treatment effects difficult. CAMELOT [41] and
PEACE [58] only reported nonfatal cases of myocardial infarction. Stroke
included transient ischemic attack in CAMELOT [41] and was limited to nonfatal
events in PART2 [57].
Among the five trials of dihydropyridine calcium-channel blockers
[35,41,43,44,47], there was no heterogeneity in the results with regard to the com-
posite of all cardiovascular events including procedures and revascularization
(P = 0.52), stroke (P = 0.81) and myocardial infarction (P = 0.16). The pooled odds
ratios were: 0.78 (CI, 0.72–0.85; P < 0.0001), 0.71 (CI, 0.55–0.92; P = 0.0015) and
0.97 (CI, 0.83–1.13; P = 70), respectively. When the analysis was limited to the
three trials involving amlodipine as the experimental agent [35,41,43], these
pooled estimates were: 0.73 (CI, 0.62–0.85; P = 0.0001) for cardiovascular events;
0.60 (CI, 0.36–0.97; P = 0.038) for stroke; and 0.69 (CI, 0.49–0.97; P = 0.033) for
myocardial infarction.
Among the placebo-controlled trials of ACE inhibitors [41,48,49,51,54,55,57,58],
there was significant heterogeneity (P ≤ 0.001) in the outcome results for all cardio-
vascular endpoints and stroke, but not for myocardial infarction (P = 0.25).
Cardiovascular events included revascularization procedures in CAMELOT [41]
and total mortality in SCAT [48], but not in the other trials [49,51,54,55,57,58].
Across the available studies [41,48,49,51,54,55,57,58], the pooled odds ratios for
ACE inhibition vs. placebo were highly significant (P < 0.0001), amounting to 0.81
(CI, 0.77–0.86) for cardiovascular events, 0.77 (CI, 0.69–0.84) for stroke and 0.80 (CI,
0.73–0.86) for myocardial infarction. In sensitivity analyses, we excluded EUROPA
[49] and PROGRESS/Per [51], two trials of perindopril given in monotherapy and
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DIABHYCAR [54], in which the difference in systolic pressure between the
ramipril and placebo group was only 1.5 mmHg. These exclusions removed the
heterogeneity for stroke (P = 0.11) and decreased the common odds ratio for stroke
to 0.63 (CI, 0.56–0.72; P < 0.0001).
In addition to the endpoints reviewed above, several secondary prevention
trials, including AASK [31,60], ABCD [61–65], BENEDICT [66,67], CALM [68],
HOPE [56], IRMA2 [69], REIN [70], RENAAL [71], IDNT2 [33–35] and a number
of earlier published smaller trials [72] demonstrated that ACE inhibitors, AR1
blockers or their combination reduce the progression of renal impairment in
patients with microalbuminuria or proteinuria, associated or not with diabetes
mellitus.
INTERPRETATION OF THE EVIDENCE
This updated overview confirmed that old and new antihypertensive drugs pro-
vide similar overall cardiovascular protection. The evidence suggested that
dihydropyridine calcium-channel blockers might offer a slight but selective ben-
efit in the prevention of stroke and inhibitors of the renin–angiotensin system in
the prevention of heart failure. For prevention of myocardial infarction, the pub-
lished results were more equivocal because of the benefit of amlodipine over
placebo [35] or valsartan [39,40] in two trials, whereas other placebo-controlled
trials of calcium-channel blockers [44,47] or ACE inhibitors [41,54,58] did not
substantiate the expected advantage with regard to cardiac outcomes.
Prevention of stroke
In 2001 [5], we already noticed that calcium-channel blockers, compared to con-
ventional therapy with diuretics and/or β–blockers, gave 13.5% (P = 0.03) more
reduction in the risk of stroke. In our 2003 review [7], we additionally included
ALLHAT/Aml [21], CONVINCE [19] and ELSA [20,22] and in our present
overview also INVEST [29] and SHELL [30]. The number of randomized patients
thereby increased from 23 454 in 2001 [5] to 67 435 in 2003 [5] and 91 893 cur-
rently. With these additional patients, the overall estimates of benefit of calcium-
channel blockers over old drugs in the prevention of stroke were 7.6% (P = 0.07)
in 2003 [5] and presently 8.0% (P = 0.03). These findings were in line with those
of consecutive overviews published by the Blood Pressure Lowering Treatment
Trialists’ Collaboration [73–75]. In 2000 [74], starting from individual patient
records and summary tabular data [73], this consortium reviewed five trials,
including INSIGHT [12], NICS [10], NORDIL [13], STOP2/CCBs [11] and VHAS
[26]. Their 2003 update [75] additionally considered AASK [31,60,76,77], ALL-
HAT/Aml [21], CONVINCE [19], ELSA [20,22], but not INVEST [29]. In these
consecutive overviews, the estimates of benefit of calcium-channel blockers over
old drugs in the prevention of stroke were 13.0% [74] and 7.0% [75], respectively.
All calcium-channel blockers bind to a specific receptor domain situated on the
α1-subunit of the L-type calcium channel [78], but amlodipine also binds to dilti-
azem receptors [78]. These pharmacologic characteristics, but more importantly,
the low probability of heterogeneity among the trials involving dihydropy-
ridines and diltiazem (P = 0.80) provided a rationale for a sensitivity analysis
combining these two subclasses of calcium-channel blockers. After exclusion of
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the two verapamil-based trials [28,29], we found a 10.0% (P = 0.02) better
prevention of stroke on calcium-channel blockers than old drugs.
In 2001 [5], we reviewed three trials comparing ACE inhibitors to conven-
tional therapy [9,11,16], which included 16 551 randomized patients. Both treat-
ment modalities gave similar protection against cerebrovascular accidents [5]. In
the present analysis, the number of relevant trials increased to five [9,11,16,21,23]
and the number of randomized patients rose to 46 553. In contrast to our former
conclusions [5], ACE inhibitors gave 10.2% less reduction in the risk of stroke
than the old antihypertensive drugs. These results are in line with the secondary
prevention trials in patients with a history of cerebrovascular disease, which
tested inhibitors of the renin system [51,79] or indapamide [80] against placebo.
Neither atenolol in TEST [79] nor perindopril in the monotherapy arm of the
PROGRESS trial [51] reduced the incidence of stroke recurrence, whereas in the
Chinese PATS trial [80] for a similar reduction in systolic blood pressure (5.0
mmHg) indapamide decreased recurrent stroke by 29%. In the EUROPA trial
[49], in patients with coronary heart disease, perindopril given on top of usual
therapy did no better than placebo in the primary prevention of stroke.
In two trials [23,24], AR1 blockers resulted in 24.4% better stroke prevention
than did the old drugs, whereas the opposite trend was observed in the doxa-
zosin arm of the ALLHAT trial (−17.5%, P = 0.04). A comprehensive overview of
observational cohort studies recently highlighted that throughout middle and
old age blood pressure is strongly and directly related to stroke mortality [1].
Hypertension is the most consistent and powerful predictor of stroke [1,81] and
is involved in nearly 70% of strokes [81]. It is therefore impossible to interpret
the stroke results of our overview without taking into account the within-trial
differences in achieved systolic blood pressure (see Chapter 30).
Prevention of myocardial infarction
We reported in 2001 [5,6] that calcium-channel blockers, compared to diuretics
and β–blockers, gave 19.2% less reduction of the risk of myocardial infarction [5].
The corresponding pooled estimate reported by the Blood Pressure Lowering
Treatment Trialists’ Collaboration was 12.0% [74]. In the present update, the
shortfall of calcium-channel blockers relative to conventional therapy disap-
peared in part as a result of the positive trend in favor of verapamil in CON-
VINCE (0.81; CI, 0.64–1.02; P = 0.08 [28]) and the similar coronary outcomes on
amlodipine and chlorthalidone in ALLHAT (0.99; CI, 0.90–1.08; P = 0.79 [21]) and
on verapamil and atenolol in INVEST (1.03; CI, 0.90–1.18; P = 0.68 [29]).
Furthermore, in our previous [5,6] as well as our current analysis, ACE inhibitors
and old drugs performed equally well in the prevention of myocardial infarc-
tion. ANBP2 [23,82] was the only actively controlled trial of ACE inhibitors,
which showed a borderline significant benefit over conventional therapy in
the prevention of fatal and nonfatal myocardial infarction (0.70; CI, 0.45–1.00;
P = 0.048). Thus, in the actively controlled trials, new drugs and conventional
therapy prevented coronary complications to the same extent. This conclusion is
supported by the observation that for myocardial infarction none of the P-values
for heterogeneity reached statistical significance.
Among eight placebo-controlled secondary prevention studies [41,48,49,51,
54,55,57,58], ACE inhibitors reduced the risk of myocardial infarction by 20%.
However, among individual trials, ACE inhibition did not lead to significantly
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less myocardial infarcts in CAMELOT/En (0.55; CI, 0.26–1.15; P = 0.11 [41]),
DIABHYCAR (0.79; CI, 0.57–1.10; P = 0.16 [54]) and PEACE (1.00; CI, 0.83–1.20;
P > 0.99 [58]). Some investigators [58] attributed these null results to the high fre-
quency of background therapy with lipid-lowering drugs and anti-platelet
agents. However, this explanation is unlikely because the use of such drugs was
similarly high in trials that demonstrated a difference in the risk of myocardial
infarction, such as EUROPA [49], VALUE [39,40] or CAMELOT/Aml [41]. More
likely explanations are that either the sample size was too small to achieve a
significant result [41] or that the difference in systolic blood pressure between
randomized groups was relatively small [54,58].
Among five placebo-controlled secondary prevention studies [35,41,43,44,47],
dihydropyridine calcium-channel blockers did not significantly decrease the
risk of myocardial infarction. However, across the three trials in which amlodip-
ine was the experimental drug, including CAMELOT/Aml [41], IDNT2 [35],
PREVENT [43], amlodipine was 31% (P = 0.033) better than placebo. These
results are in line with those of the VALUE trial [39,40], in which amlodipine
showed a 15% benefit vs. valsartan (P = 0.02). These observations raise the ques-
tion whether for prevention of myocardial infarction all dihydropyridine cal-
cium-channel blockers behave as a single class. Indeed, among individual trials,
point estimates trended to be higher than unity or were equal to unity for nisol-
dipine vs. enalapril in the revised ABCD/HT results (3.30; CI, 1.50–7.10; P =
0.029 [64]); for nisoldipine vs. placebo in NICOLE (1.25; CI, 0.56–2.86; P = 0.58
[47]); for nifedipine vs. co-amilozide in INSIGHT [12] for fatal cases (3.22; CI,
1.18–8.80; P = 0.017) as well as for nonfatal infarcts (1.09; CI, 0.76–1.58; P = 0.52);
for nifedipine vs. ACE inhibitors in JMIC-B (1.31; CI, 0.63–2.74; P = 0.47); and for
nifedipine vs. placebo in ACTION (1.04; CI, 0.88–1.24; P = 0.62 [44]). Differences
between randomized groups in achieved systolic blood pressure were small and
nonsignificant in ABCD/HT [61] and INSIGHT [12], but favored the calcium-
channel blocker in NICOLE (9.1 mmHg [47]), JMIC-B (2.0 mmHg [83]) and
ACTION (6.0 mmHg [44]).
The results of the blood pressure lowering limb of ASCOT [84], due to be pub-
lished in 2005, might shed more light on the prevention of myocardial infarction.
In a 2 × 2 factorial design [84,85], 19 342 hypertensive patients were randomized
to amlodipine combined or not with perindopril or to atenolol combined or not
with bendrofluazide (open-label treatment with blinded endpoint validation),
while a subgroup of 10 305 patients received double-blind treatment with either
atorvastatin or placebo. The primary endpoint was the combination of death
from coronary heart disease and nonfatal myocardial infarction [84,85]. Because
of benefit, the atorvastatin and amlodipine arms stopped in September 2002 [85]
and November 2004, respectively. Achieved blood pressure was lower on new
vs. old antihypertensive drugs. An interaction between blood pressure and lipid
lowering might therefore have contributed to the immediate separation of the
Kaplan–Meier estimates in the lipid trial [85].
Prevention of heart failure
The risk of heart failure was higher on calcium-channel blockers than on conven-
tional therapy without heterogeneity among the trials. In individual studies, the
risk of heart failure was significantly increased on nifedipine GITS in INSIGHT
(2.18; CI, 1.06–2.18; P = 0.03 [12]); on amlodipine in ALLHAT (1.38; CI, 1.25–1.50;
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P < 0.001 [21]); and on verapamil in CONVINCE (odds ratio 1.30; CI, 1.00–1.69;
P = 0.05 [19]). Calcium-channel blockers reduce left ventricular afterload.
However, neuroendocrine activation in response to arterial vasodilatation, as for
instance exemplified by the increase in heart rate on nifedipine in ACTION [44]
as well as the direct negative inotropic action on the myocardium may elicit
heart failure in predisposed patients [86]. Nevertheless, on top of diuretics
and/or ACE inhibitors, long-acting dihydropyridines [87,88], diltiazem [89] and
verapamil [90] can be used in patients with left ventricular dysfunction to lower
blood pressure or to treat angina pectoris. The reduction of heart failure on
nifedipine GITS vs. placebo in ACTION (0.71; CI, 0.54–0.94; P = 0.015 [44]) was
unexpected, but might be due to the 6.0 mmHg lower systolic blood pressure in
the patients on nifedipine or to unbalanced prescription of background medica-
tions in favor of the actively treated patients. The ACTION report [44], similarly
to several other studies [54,55,58], did not provide any information on concomi-
tant medications after randomization.
Among the trials of new vs. old drugs [7], all newer agents on average per-
formed 23.1% worse in the prevention of heart failure than conventional therapy.
This is not surprising because both diuretics and β–blockers belong to the stan-
dard of care for this condition [91]. The same is true for ACE inhibitors given on
top of digitalis and diuretics. AR1 blockers, perhaps with the exception of can-
desartan titrated up to 32 mg daily [92–95], are only indicated as alternative to
ACE inhibitors when class-specific side-effects, such as cough, occur [91,96–98].
Two trials of the combination of ACE inhibitors and AR1 blockers in patients
with heart failure reported contradictory results [94,99].
The higher risk of heart failure on lisinopril in ALLHAT (1.19; CI, 1.07–1.31;
P < 0.001 [21]) is contra-intuitive, whereas the results of the ALLHAT doxazosin
arm (1.80; CI, 1.61–2.02; P < 0.001 [14,32]) were in line with previous studies
[100]. In trials of ACE inhibitors in patients with heart failure [91] or high cardio-
vascular risk [51,55], these agents were always combined with diuretics. In con-
trast to current guidelines [3,101], in therapy-resistant ALLHAT patients,
lisinopril had to be associated with sympatholytic agents and/or hydralazine
before diuretics could be added [21]. Furthermore, heart failure in ALLHAT was
only a component of a secondary endpoint, which did not lead to an increase in
cardiovascular [21] or total [14,21] mortality. At randomization, 90.2% of the
ALLHAT patients were already on antihypertensive drugs, diuretics in most
cases. Thus, the patients allocated amlodipine, lisinopril or doxazosin were at
risk of rapidly losing the protection of their previous diuretic treatment, whereas
in those of the chlorthalidone group the volume-dependent signs and symptoms
of heart failure remained suppressed. These design features of ALLHAT likely
explain why the Kaplan–Meier estimates for heart failure separated immedi-
ately after randomization [14,21,32]. Because of the weight of ALLHAT in our
overview, pooled estimates including this trial must be cautiously interpreted.
In the main analysis of the VALUE trial [39], the risk of heart failure was
slightly less on valsartan than amlodipine (0.89; CI, 0.77–1.03; P = 0.12). This
trend reached borderline significance in two post-hoc analyses [39,40]. First, the
VALUE investigators artificially subdivided the follow-up period into consecu-
tive intervals characterized by progressively decreasing between-group differ-
ences in systolic blood pressure [39]. In the interval from 36 to 48 months the risk
was 0.69 (CI, 0.51–0.94). However, these time-interval specific analyses were
biased for all periods but the first 0–3 months, because event rates in each
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sequential period were conditional on those occurring earlier [39,40]. Patients
continuing to each subsequent period were therefore unbalanced with regard to
risk and randomization. Second, in an accompanying paper [40], the VALUE
consortium performed serial median matching using the systolic blood pressure
level at 6 months and found that the risk of heart failure on valsartan vs.
amlodipine was 0.81(CI, 0.66–0.99; P = 0.04). This matched-pair approach [40]
accounted for the attained systolic pressure (within 2 mmHg) and other cardio-
vascular risk factors, but excluded 5233 patients (34.3%) whose systolic pressure
was too high on valsartan or too low on amlodipine to allow matching.
CONCLUSIONS
Most trials published over the past decade mainly enrolled middle-aged and
older patients of male sex at high cardiovascular risk who had previous compli-
cations, associated diseases or both. To what extent their findings can be reason-
ably extrapolated to younger and female patients in a routine clinical setting
remains a matter of concern [102].
This overview suggested that dihydropyridine calcium-channel blockers
might offer a selective benefit in the prevention of stroke and inhibitors of the
renin–angiotensin system in the prevention of heart failure, resulting in a
similar overall protection against cardiovascular complications. This is in
contrast to some individual studies showing greater [55,56] or reduced [14,32]
cardiovascular benefit in patients treated with newer drugs as compared with
conventional antihypertensive therapy. However, outcome results should
never be interpreted without taking into account differences in achieved blood
pressure between randomized groups. In Chapter 30, we will investigate to
what extent blood pressure reduction accounts for results of individual
outcome trials.
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ACRONYMS OF TRIALS
AASK (the African American Study of Kidney disease and hypertension
[31,60,76,77]); ABCD (Appropriate Blood Pressure Control in Diabetes trial
[61–65]); ABCD/HT (Appropriate Blood Pressure Control in Diabetes trial –
nisoldipine vs. enalapril in hypertensive patients [61,63,64]); ABCD/NT
(Appropriate Blood Pressure Control in Diabetes trial – tight vs. usual blood
pressure control in normotensive hypertensive patients [65]); ACTION (A
Coronary disease Trial Investigating Outcome with Nifedipine GITS [44,45]);
ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
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Attack Trial [21]); ALLHAT/Aml (Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial – amlodipine vs. chlorthalidone [21]);
ALLHAT/Dox (Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial – doxazosin vs. chlorthalidone [14,32]); ALLHAT/Lis
(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
– lisinopril vs. chlorthalidone [21]); ANBP2 (Australian comparative outcome
trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment
of hypertension in the elderly [23]); ASCOT (the Anglo-Scandinavian Cardiac
Outcomes Trial [84,85]); ATMH (Australian Trial in Mild Hypertension [103]);
BENEDICT (BErgamo NEphrologic DIabetes Complications Trial [66,67]);
CAMELOT (Comparison of AMlodipine vs. Enalapril to Limit Occurrences of
Thrombosis [41]); CAMELOT/Aml (Comparison of AMlodipine vs. Enalapril to
Limit Occurrences of Thrombosis – amlodipine vs. placebo [41]); CAMELOT/En
(Comparison of AMlodipine vs. Enalapril to Limit Occurrences of Thrombosis –
enalapril vs. placebo [41]); CASTEL (CArdiovascular STudy in the ELderly
[104]); CALM (CAndesartan and Lisinopril Microalbuminuria study [68]);
CONVINCE (Controlled Onset Verapamil Investigation of Cardiovascular
Endpoints Trial [19]); CAPPP (Captopril Prevention Project [9,105]); CON-
VINCE (Controlled Onset Verapamil Investigation of Cardiovascular Endpoints
Trial [19]); DIABHYCAR (the noninsulin-dependent DIAbetes, HYpertension,
microalbuminuria or proteinuria, CArdiovascular events, and Ramipril study
[52–54]); ELSA (European Lacidipine Study on Atherosclerosis [20,22]);
EUROPA (EURopean trial On reduction of cardiac events with Perindopril in
stable coronary Artery disease [49]); EWPHE (trial conducted by the European
Working Party on High Blood Pressure in the Elderly [106,107]); HEP (trial of
Hypertension in Elderly Patients in primary care [108]); HDFP (Hypertension
Detection and Follow-Up Program [109,110]); HOPE (Heart Outcomes
Prevention Evaluation Study [55,56]); HOT (Hypertension Optimal Treatment
trial [111]); HOT/LH (Hypertension Optimal Treatment trial [111] – 80 vs. 90
mmHg as target diastolic pressure); HOT/MH (Hypertension Optimal
Treatment trial [111] – 85 vs. 90 mmHg as target diastolic pressure); HYVET
(HYpertension in the Very Elderly Trial pilot trial [25]); HYVET/AD
(HYpertension in the Very Elderly Trial pilot trial – ACE inhibition vs. diuretic
treatment [25]); HYVET/BP (HYpertension in the Very Elderly Trial pilot trial –
blood pressure lowering drugs vs. no treatment [25]); IDNT2 (Irbesartan
Diabetic Nephropathy Trial in patients with type-2 diabetes mellitus [33–35]);
INSIGHT (International Nifedipine GITS Study – Intervention as a Goal for
Hypertension Therapy [12,112]); IRMA2 (Irbesartan in patients with type-2 dia-
betes and MicroAlbuminuria study[69]); INVEST (INternational VErapamil
SR/trandolapril STudy [29]); JMIC-B (the Japan Multicenter Investigation for
Cardiovascular diseases-B [83]); LIFE (Losartan Intervention For Endpoint
Reduction in hypertension study [17,18,113,114]); LIFE/All (Losartan
Intervention For Endpoint Reduction in hypertension study – all patients [18]);
LIFE/DM (Losartan Intervention For Endpoint Reduction in hypertension study
– diabetic subgroup [17]); HSCS (Hypertension-Stroke Cooperative Study
[115]); MIDAS (Multicenter Isradipine Diuretic Atherosclerosis Study [8]);
MIDAS/NICS/VHAS (combined results of MIDAS, [8] NICS [10] and VHAS
[15]); MRC1 (Medical Research Council trial of treatment of mild hypertension
[116]); MRC2 (Medical Research Council trial of treatment of hypertension
in older adults [117]); NICOLE (NIsoldipine in COronary artery disease in
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LEuven [46,47]); NICS (National Intervention Cooperative Study in Elderly
Hypertensives [10]); NORDIL (Nordic Diltiazem Study [13]); OSLO (Oslo
Study on the Treatment of Mild Hypertension [27]); PART2 (Prevention of
Atherosclerosis with Ramipril Trial [57]); PART2/SCAT (combined results of
PART2 [57] and SCAT [48]); PATS (Post-stroke Antihypertensive Treatment
Study [80]); PEACE (Prevention of Events with Angiotensin Converting Enzyme
inhibition [58]); PREVENT (Prospective Randomized Evaluation of the Vascular
Effects Norvasc Trial [42,43]); PROGRESS (Perindopril PrOtection Against
Recurrent Stroke Study [51,59,118]); PROGRESS/Com (Perindopril PrOtection
Against Recurrent Stroke Study [51,59,118] – group on combined therapy);
PROGRESS/Per (Perindopril PrOtection Against Recurrent Stroke Study
[51,59,118] – group on single-drug treatment); REIN (Ramipril Efficacy In
Nephropathy trial [70]); RENAAL (Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan [71]); RCT70-80 (combined results of 4
smaller trials published from 1970 through 1980, including HSCS, [115] OSLO,
[27] USPHS, [119] and VACS [120]); SCAT (Simvastatin/Enalapril Coronary
Atherosclerosis Trial [48]); SCOPE (Study on COgnition and Prognosis in the
Elderly [24,121,122]); SHELL (Systolic Hypertension in the Elderly Long-term
Lacidipine trial [30]); SHEP (Systolic Hypertension in the Elderly Program
[123,124]); STONE (Shanghai Trial of Nifedipine in the Elderly [125]); STOP1
(Swedish Trial in Old Patients with hypertension [126]); STOP2 (Swedish
Trial in Old Patients with hypertension–2 [11]); STOP2/ACEIs (angiotensin-
converting enzyme inhibitor arm of STOP2 [11]); STOP2/CCBs (calcium-
channel blocker arm of STOP2 [11]); Syst-China (Systolic Hypertension in China
trial [127,128]); Syst-Eur (Systolic Hypertension in Europe trial [129–131]); TEST
(Tenormin after Stroke and TIA [79]); UKPDS (UKPDS Hypertension in
Diabetes Study [16,132]); UKPDS/CA (UKPDS Hypertension in Diabetes Study
– captopril vs. atenolol [16]); UKPDS/LH (UKPDS Hypertension in Diabetes
Study – low vs. high on-treatment blood pressure [132]); USPHS (United States
Public Health Service Hospitals Cooperative Study [119]); VACS (Veterans
Administration Cooperative Study in patients with diastolic blood pressure
averaging 90–114 mmHg [120]); VALUE (Valsartan Antihypertensive Long-term
Use Evaluation [36–40]); VHAS (Verapamil in Hypertension and Atherosclerosis
Study [26])
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